Journal
CLINICA CHIMICA ACTA
Volume 440, Issue -, Pages 79-86Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.cca.2014.10.044
Keywords
Proprotein convertase subtilisin/kexin type 9; Low-density lipoprotein cholesterol; Dyslipidemia; Review
Categories
Funding
- National Natural Scientific Foundation of China [81070171, 81241121]
- Specialized Research Fund for the Doctoral Program of Higher Education of China [20111106110013]
- Capital Special Foundation for Clinical Application [Z121107001012015]
Ask authors/readers for more resources
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a newly-recognized protein, plays a key role in regulating cholesterol homeostasis. PCSK9 reduces hepatic low-density lipoprotein receptors (LDLRs) thereby increasing LDL-cholesterol (LDL-C). Recently, biologic and genetic research proposed several approaches to inhibit or reduce PCSK9 to improve lipid profile and cardiovascular performance in patients with dyslipidemia, particularly hyper-cholesterolemia. Of note, PCSK9 is a secreted protein under tight control by multiple modulators. Therefore, elucidating the factors that influence PCSK9 would enhance our understanding of PCSK9 and potentially day-to-day management of these patients at high cardiovascular risk. This review will focus on genetic variants, physiologic processes, pharmacologic agents and pathologic conditions related to PCSK9 in order to assess current and future therapeutic strategies targeting this molecule. (C) 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available